{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:33:34Z","timestamp":1790253214295,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112663","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T05:21:45Z","timestamp":1722230505000},"page":"112663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments"],"prefix":"10.1016","volume":"139","author":[{"given":"Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-3264","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.intimp.2024.112663_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms23137484","article-title":"Probing the Skin-Brain Axis: New Vistas Using Mouse Models","volume":"23","author":"Weiglein","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2024.112663_b0010","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2024.112663_b0015","article-title":"The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112663_b0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","article-title":"New and Emerging Systemic Treatments for Atopic Dermatitis","volume":"80","author":"Newsom","year":"2020","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.intimp.2024.112663_b0025","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","article-title":"The Role of Interleukins 4 and\/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergology International : Official Journal of the Japanese Society of Allergology."},{"issue":"3 Suppl 1","key":"10.1016\/j.intimp.2024.112663_b0040","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jaad.2017.12.020","article-title":"T-cell inhibitors for atopic dermatitis","volume":"78","author":"Tidwell","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9789","key":"10.1016\/j.intimp.2024.112663_b0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0050","doi-asserted-by":"crossref","first-page":"e000237","DOI":"10.1136\/rmdopen-2015-000237","article-title":"Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study","volume":"2","author":"D'Agostino","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.intimp.2024.112663_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2020.02.002","article-title":"The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers","volume":"52","author":"Wang","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0060","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and Co-inhibitory Pathways in Autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.112663_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102333","article-title":"Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases","volume":"104","author":"Huang","year":"2019","journal-title":"J Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41423-018-0086-z","article-title":"Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy","volume":"16","author":"Li","year":"2019","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115492","article-title":"Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha","volume":"210","author":"Li","year":"2023","journal-title":"Biochem Pharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112663_b0080","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.humimm.2010.07.007","article-title":"CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions","volume":"71","author":"Laurent","year":"2010","journal-title":"Hum Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2249.2006.03218.x","article-title":"Autoantibodies against CD28 are associated with atopic diseases","volume":"146","author":"Neuber","year":"2006","journal-title":"Clin Exp Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2567.2006.02362.x","article-title":"Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression","volume":"118","author":"Oderup","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2024.112663_b0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.0105-2896.2006.00423.x","article-title":"Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation","volume":"212","author":"Izcue","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112663_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0105","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.immuni.2024.01.019","article-title":"Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells","volume":"57","author":"Ding","year":"2024","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jid.2021.06.026","article-title":"Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses","volume":"142","author":"Tanaka","year":"2022","journal-title":"J Invest Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12974-018-1191-8","article-title":"Impaired CD8 T cell antiviral immunity following acute spinal cord injury","volume":"15","author":"Norden","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2024.112663_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.877936","article-title":"PD-1\/PD-L Axis in Neuroinflammation: New Insights","volume":"13","author":"Manenti","year":"2022","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","article-title":"TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2024.112663_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952338","article-title":"Galectin-9 contributes to the pathogenesis of atopic dermatitis via T cell immunoglobulin mucin-3","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0140","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0155","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/JID.2015.404","article-title":"Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase","volume":"136","author":"Inozume","year":"2016","journal-title":"J Invest Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0170","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","article-title":"synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy","volume":"15","author":"Lupo","year":"2024","journal-title":"Nat Commun."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med."},{"issue":"6475","key":"10.1016\/j.intimp.2024.112663_b0180","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0190","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1172\/JCI74589","article-title":"Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity","volume":"124","author":"Flies","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"522","key":"10.1016\/j.intimp.2024.112663_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1159","article-title":"PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus","volume":"11","author":"Han","year":"2019","journal-title":"Sci Transl Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gutjnl-2022-326928","article-title":"Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts","volume":"72","author":"Li","year":"2023","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103085","article-title":"Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases","volume":"21","author":"Gertel","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clim.2010.07.012","article-title":"Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity","volume":"137","author":"Liu","year":"2010","journal-title":"Clin Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","article-title":"Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells","volume":"15","author":"Shaw","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0230","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jid.2022.11.009","article-title":"Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases","volume":"143","author":"Iriki","year":"2023","journal-title":"J Invest Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0235","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","article-title":"The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses","volume":"44","author":"Ward-Kavanagh","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/cmi.2018.8","article-title":"Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation","volume":"16","author":"Kumar","year":"2019","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0250","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2015.00394","article-title":"Mast Cells as Regulators of T Cell Responses","volume":"6","author":"Bulfone-Paus","year":"2015","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.immuni.2018.05.003","article-title":"Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells","volume":"48","author":"Halim","year":"2018","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2024.112663_b0260","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.4049\/jimmunol.173.8.5247","article-title":"T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells","volume":"173","author":"Kashiwakura","year":"2004","journal-title":"J Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2024.112663_b0265","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2009-05-220004","article-title":"Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40\/OX40L axis toward Th17-cell differentiation","volume":"114","author":"Piconese","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0270","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/eji.201445163","article-title":"OX40 blockade inhibits house dust mite driven allergic lung inflammation in mice and in vitro allergic responses in humans","volume":"45","author":"Burrows","year":"2015","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588682","article-title":"The Role of GITR\/GITRL Interaction in Autoimmune Diseases","volume":"11","author":"Tian","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0280","doi-asserted-by":"crossref","unstructured":"Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. European journal of cancer (Oxford, England : 1990). 2016 Nov;67:1-10; http:\/\/doi.org\/10.1016\/j.ejca.2016.06.028.","DOI":"10.1016\/j.ejca.2016.06.028"},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cytogfr.2013.12.003","article-title":"Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection","volume":"25","author":"Clouthier","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.intimp.2024.112663_b0290","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.179.9.5916","article-title":"Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells","volume":"179","author":"Ronchetti","year":"2007","journal-title":"J Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/1756-185X.12451","article-title":"Aberrant GITR expression on different T cell subsets and the regulation by glucocorticoid in systemic lupus erythematosus","volume":"19","author":"Sun","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0300","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.0007-0963.2004.05891.x","article-title":"Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris","volume":"150","author":"Lew","year":"2004","journal-title":"Br J Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0305","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.3390\/ijms18122526","article-title":"The Genetic Basis of Psoriasis","volume":"18","author":"Capon","year":"2017","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2024.112663_b0310","doi-asserted-by":"crossref","unstructured":"Bunte K, Beikler T. Th17 Cells and the IL-23\/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int J Mol Sci. 2019 Jul 10;20(14); http:\/\/doi.org\/10.3390\/ijms20143394.","DOI":"10.3390\/ijms20143394"},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0315","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941071","article-title":"Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis","volume":"13","author":"Kamata","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0330","first-page":"186","article-title":"DNA structures decorated with cathepsin G\/secretory leukocyte proteinase inhibitor stimulate IFNI production by plasmacytoid dendritic cells","volume":"2","author":"Skrzeczynska-Moncznik","year":"2013","journal-title":"American Journal of Clinical and Experimental Immunology."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0335","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s13238-018-0505-z","article-title":"IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis","volume":"9","author":"Hou","year":"2018","journal-title":"Protein Cell"},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0340","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.192.5.681","article-title":"Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells","volume":"192","author":"Abrams","year":"2000","journal-title":"J Exp Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0345","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.gene.2015.05.051","article-title":"Lack of association between cytotoxic T-lymphocyte antigen-4+49A\/G polymorphism and psoriasis and vitiligo: A meta-analysis of case-control studies","volume":"568","author":"Liang","year":"2015","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0350","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jdermsci.2017.11.007","article-title":"The expression of mCTLA-4 in skin lesion inversely correlates with the severity of psoriasis","volume":"89","author":"Liu","year":"2018","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.intimp.2024.112663_b0355","doi-asserted-by":"crossref","first-page":"1233514","DOI":"10.3389\/fimmu.2023.1233514","article-title":"Alleviating psoriatic skin inflammation through augmentation of Treg cells via CTLA-4 signaling peptide","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112663_b0360","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.112663_b0365","series-title":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases","article-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Abatacept. LiverTox,","year":"2012"},{"issue":"9","key":"10.1016\/j.intimp.2024.112663_b0370","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0375","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int."},{"issue":"11","key":"10.1016\/j.intimp.2024.112663_b0380","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2021.3492","article-title":"Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial","volume":"157","author":"Harris","year":"2021","journal-title":"JAMA Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0385","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jaci.2015.11.021","article-title":"Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells","volume":"137","author":"Kim","year":"2016","journal-title":"J Allergy Clin Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112663_b0390","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jid.2021.03.011","article-title":"PD-1 Expression Defines Epidermal CD8(+)CD103(+) T Cells Preferentially Producing IL-17A and Using Skewed TCR Repertoire in Psoriasis","volume":"141","author":"Phadungsaksawasdi","year":"2021","journal-title":"J Invest Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112663_b0395","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00403-016-1679-y","article-title":"Decreased PD-1 positive blood follicular helper T cells in patients with psoriasis","volume":"308","author":"Shin","year":"2016","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.intimp.2024.112663_b0400","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2017.06.002","article-title":"TCR(+)CD3(+)CD4(-)CD8(-) effector T cells in psoriasis","volume":"181","author":"Brandt","year":"2017","journal-title":"Clin Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0405","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4049\/jimmunol.1500448","article-title":"Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate gammadelta-Low T Cells","volume":"195","author":"Imai","year":"2015","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0410","doi-asserted-by":"crossref","first-page":"5385102","DOI":"10.1155\/2017\/5385102","article-title":"Suppressed Programmed Death 1 Expression on CD4(+) and CD8(+) T Cells in Psoriatic Patients","volume":"2017","author":"Bartosinska","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0415","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5114\/ada.2018.75609","article-title":"Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis","volume":"35","author":"Bartosinska","year":"2018","journal-title":"Postepy Dermatol Alergol."},{"key":"10.1016\/j.intimp.2024.112663_b0420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2024.112663_b0425","doi-asserted-by":"crossref","unstructured":"Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, et al. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production. Sci Transl Med. 2018 Sep 26;10(460); http:\/\/doi.org\/10.1126\/scitranslmed.aar8356.","DOI":"10.1126\/scitranslmed.aar8356"},{"key":"10.1016\/j.intimp.2024.112663_b0430","doi-asserted-by":"crossref","unstructured":"Jung CJ, Yang HJ, Bang SH, Lee WJ, Won CH, Lee MW, et al. Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression. J Clin Med. 2021 Nov 7;10(21); http:\/\/doi.org\/10.3390\/jcm10215200.","DOI":"10.3390\/jcm10215200"},{"key":"10.1016\/j.intimp.2024.112663_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134179","article-title":"The Impact of Biologic Treatment on PD-1\/PD-L1 Pathway Disturbances in Psoriasis","author":"Adamczyk","year":"2023","journal-title":"J Clin Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0440","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00403-015-1588-5","article-title":"Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis","volume":"307","author":"Kim","year":"2015","journal-title":"Arch Dermatol Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.112663_b0445","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jid.2016.04.032","article-title":"The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes","volume":"136","author":"Kim","year":"2016","journal-title":"J Invest Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0450","article-title":"Investigation of the PD-1\/PD-L1 Expression in the Lesional Skins of Patients With Psoriasis","volume":"13","author":"Emre","year":"2023","journal-title":"Dermatol Pract Concept."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0455","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1002\/term.2423","article-title":"Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1\/programmed death ligand-1 (PD-1\/PD-L1) pathway","volume":"12","author":"Kim","year":"2018","journal-title":"J Tissue Eng Regen Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.112663_b0460","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jid.2023.02.018","article-title":"PD-L1 Enhanced by cis-Urocanic Acid on Langerhans Cells Inhibits Vgamma4(+) gammadeltaT17 Cells in Imiquimod-Induced Skin Inflammation","volume":"143","author":"Yeh","year":"2023","journal-title":"J Invest Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0465","first-page":"809","volume":"34","author":"Jia","year":"2023","journal-title":"Tumor-Derived PD-L1+ Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment."},{"key":"10.1016\/j.intimp.2024.112663_b0470","unstructured":"ClinicalTraials.gov. Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685. [cited; https:\/\/clinicaltrials.gov\/study\/NCT05332704, 2022(accessed 25 June 2024)."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0475","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2009.04.012","article-title":"Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and\/or Th17-mediated skin inflammation","volume":"132","author":"Niwa","year":"2009","journal-title":"Clin Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0480","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2340\/00015555-1285","article-title":"Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis","volume":"92","author":"Kanai","year":"2012","journal-title":"Acta Derm Venereol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0485","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1398-9995.2006.01130.x","article-title":"Regulatory mechanisms of galectin-9 and eotaxin-3 synthesis in epidermal keratinocytes: possible involvement of galectin-9 in dermal eosinophilia of Th1-polarized skin inflammation","volume":"61","author":"Igawa","year":"2006","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2023.110741","article-title":"The elevation of plasma galectin-9 levels in patients with psoriasis and its associations with inflammatory and immune checkpoint molecules in skin tissues","volume":"85","author":"Chagan-Yasutan","year":"2024","journal-title":"Hum Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0495","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.molimm.2023.03.008","article-title":"Gal-9\/Tim-3 signaling pathway activation suppresses the generation of Th17 cells and promotes the induction of Foxp3(+) regulatory T cells in renal ischemia-reperfusion injury","volume":"156","author":"Wang","year":"2023","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0500","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ced.13414","article-title":"TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis","volume":"43","author":"Wang","year":"2018","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.intimp.2024.112663_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107722","article-title":"Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis","volume":"96","author":"Yu","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.112663_b0510","article-title":"DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease","volume":"1(1):ltaa004","author":"Jacobs","year":"2021","journal-title":"Immunother Adv."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0515","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep."},{"issue":"23","key":"10.1016\/j.intimp.2024.112663_b0520","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.7150\/thno.45614","article-title":"Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of skin macrophages in Vsir(-\/-) murine psoriasis","volume":"10","author":"Qie","year":"2020","journal-title":"Theranostics."},{"key":"10.1016\/j.intimp.2024.112663_b0525","article-title":"Agonistic nanobodies and antibodies to human VISTA","volume":"Jan-Dec;13(1):2003281","author":"Ma","year":"2021","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0530","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/bph.15357","article-title":"M351\u20130056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA","volume":"178","author":"Hu","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0535","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.jid.2018.05.021","article-title":"Proportion of CD4(+)CD49b(+)LAG-3(+) Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index","volume":"138","author":"Kim","year":"2018","journal-title":"J Invest Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112663_b0540","doi-asserted-by":"crossref","first-page":"e967146","DOI":"10.4161\/21624011.2014.967146","article-title":"Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity","volume":"3","author":"Castelli","year":"2014","journal-title":"Oncoimmunology."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0545","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2006.12.005","article-title":"The pathogenic role of tissue-resident immune cells in psoriasis","volume":"28","author":"Boyman","year":"2007","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0550","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cpt.2091","article-title":"Depletion of LAG-3(+) T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781","volume":"109","author":"Ellis","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0555","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00403-002-0363-6","article-title":"Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin","volume":"294","author":"Matsumura","year":"2003","journal-title":"Arch Dermatol Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0560","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1111\/j.1468-3083.2012.04587.x","article-title":"OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity","volume":"27","author":"Ilves","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV."},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0565","article-title":"Lymphocyte mass cytometry identifies a CD3-CD4+ cell subset with a potential role in psoriasis","volume":"4","author":"Guo","year":"2019","journal-title":"JCI Insight."},{"issue":"30","key":"10.1016\/j.intimp.2024.112663_b0570","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau2042","article-title":"The TNFRSF members CD27 and OX40 coordinately limit T(H)17 differentiation in regulatory T cells","volume":"3","author":"Remedios","year":"2018","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112663_b0575","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jdv.14313","article-title":"Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis","volume":"31","author":"Papp","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0580","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/exd.14270","article-title":"Mouse models of atopic dermatitis: a critical reappraisal","volume":"30","author":"Gilhar","year":"2021","journal-title":"Exp Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0585","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 Cytokines and Atopic Dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"Journal of Clinical & Cellular Immunology."},{"issue":"2 Suppl 2","key":"10.1016\/j.intimp.2024.112663_b0590","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0595","article-title":"CD1d(hi)PD-L1(hi)CD27(+) Regulatory Natural Killer Subset Suppresses Atopic Dermatitis","volume":"12","author":"Min","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0600","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0605","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/1346-8138.14696","article-title":"Expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain on CD4(+) T cells in patients with atopic dermatitis","volume":"46","author":"Kurita","year":"2019","journal-title":"J Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0610","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1399-3038.2005.00274.x","article-title":"CTLA-4 expression in T cells of patients with atopic dermatitis","volume":"16","author":"Choi","year":"2005","journal-title":"Pediatr Allergy Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.734645","article-title":"Increased Frequency of CTLA-4 and PD-1 Expressing Regulatory T Cells and Basophils With an Activating Profile in Infants With Moderate-to-Severe Atopic Dermatitis Hypersensitized to Food Allergens","volume":"9","author":"Bilbao","year":"2021","journal-title":"Front Pediatr."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0620","doi-asserted-by":"crossref","first-page":"7936","DOI":"10.1038\/s41598-023-35139-y","article-title":"CTLA-4 suppresses hapten-induced contact hypersensitivity in atopic dermatitis model mice","volume":"13","author":"Tetsu","year":"2023","journal-title":"Sci Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0625","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jcmm.12806","article-title":"Atopic dermatitis induces the expansion of thymus-derived regulatory T cells exhibiting a Th2-like phenotype in mice","volume":"20","author":"Moosbrugger-Martinz","year":"2016","journal-title":"J Cell Mol Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0630","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdermsci.2024.03.007","article-title":"IL-4-induced decrease in both the number and CTLA-4 expression of T(reg) impairs suppression of Th2 type inflammation in severe atopic dermatitis","volume":"114","author":"Wang","year":"2024","journal-title":"J Dermatol Sci."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2024.112663_b0635","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/08923970701675101","article-title":"Expression of Co-stimulatory molecules on langerhans cells in lesional epidermis of human atopic dermatitis","volume":"29","author":"Fesenkova","year":"2007","journal-title":"Immunopharmacol Immunotoxicol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112663_b0640","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s004030100263","article-title":"In situ expression of the costimulatory molecules CD80 and CD86 on langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis","volume":"293","author":"Schuller","year":"2001","journal-title":"Arch Dermatol Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.112663_b0645","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.4049\/jimmunol.160.9.4622","article-title":"Enhanced expression of B7.2 (CD86) in patients with atopic dermatitis: a potential role in the modulation of IgE synthesis","volume":"160","author":"Jirapongsananuruk","year":"1998","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0650","article-title":"Expression and functional role of co-stimulatory molecules in CD40+IL-4-stimulated B cells from atopic and non-atopic donors","volume":"Jul-Aug;80(4):287\u201391","author":"Oberwalleney","year":"2000","journal-title":"Acta Derm Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112663_b0655","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1034\/j.1600-0625.2003.120111.x","article-title":"Alteration in the production of IL-10 and IL-12 and aberrant expression of CD23, CD83 and CD86 by monocytes or monocyte-derived dendritic cells from atopic dermatitis patients","volume":"12","author":"Aiba","year":"2003","journal-title":"Exp Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0660","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2133.2005.07080.x","article-title":"Polymorphisms within the CTLA4 gene are associated with infant atopic dermatitis","volume":"154","author":"Jones","year":"2006","journal-title":"Br J Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0665","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaci.2010.05.045","article-title":"MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4","volume":"126","author":"Sonkoly","year":"2010","journal-title":"J Allergy Clin Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112663_b0670","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1067\/mai.2001.119740","article-title":"The role of CD28-B7 costimulation in allergen-induced cytokine release by bronchial mucosa from patients with moderately severe asthma","volume":"108","author":"Lordan","year":"2001","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0675","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785549","article-title":"Crosstalk Between Circulating Follicular T Helper Cells and Regulatory B Cells in Children With Extrinsic Atopic Dermatitis","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0680","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.imlet.2017.04.010","article-title":"Expansion of circulating follicular T helper cells associates with disease severity in childhood atopic dermatitis","volume":"189","author":"Szab\u00f3","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2024.112663_b0685","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.3389\/fmicb.2018.02414","article-title":"A Probiotic Mixture Regulates T Cell Balance and Reduces Atopic Dermatitis Symptoms in Mice","volume":"9","author":"Kim","year":"2018","journal-title":"Front Microbiol."},{"issue":"21","key":"10.1016\/j.intimp.2024.112663_b0690","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111898","article-title":"New Insights into the Role of PD-1 and Its Ligands in Allergic Disease","volume":"22","author":"Galvan Morales","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"7","key":"10.1016\/j.intimp.2024.112663_b0695","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1346-8138.12884","article-title":"Elevated serum galectin-9 levels in patients with atopic dermatitis","volume":"42","author":"Nakajima","year":"2015","journal-title":"J Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0700","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040947","article-title":"The Role of Galectin-9 as Mediator of Atopic Dermatitis: Effect on Keratinocytes","volume":"10","author":"Correa","year":"2021","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0705","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/08923973.2021.1925907","article-title":"VISTA-Ig ameliorates OXA-induced allergic dermatitis symptoms in mice","volume":"43","author":"Guo","year":"2021","journal-title":"Immunopharmacol Immunotoxicol."},{"key":"10.1016\/j.intimp.2024.112663_b0710","article-title":"The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis","volume":"31;100(6):adv00099","author":"Elsner","year":"2020","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0715","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2011.05.016","article-title":"Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets","volume":"128","author":"Fujita","year":"2011","journal-title":"J Allergy Clin Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0720","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122578","article-title":"OX40L-OX40 Signaling in Atopic Dermatitis","volume":"10","author":"Furue","year":"2021","journal-title":"J Clin Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.112663_b0725","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI33559","article-title":"In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation","volume":"117","author":"Seshasayee","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0730","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J Dermatol Sci."},{"issue":"10372","key":"10.1016\/j.intimp.2024.112663_b0735","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0740","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0745","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0750","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2340\/00015555-0118","article-title":"Glucocorticoid-induced tumour necrosis factor receptor (GITR) and its ligand (GITRL) in atopic dermatitis","volume":"86","author":"Baumgartner-Nielsen","year":"2006","journal-title":"Acta Derm Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0755","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2222.2012.03956.x","article-title":"Induction of GITRL expression in human keratinocytes by Th2 cytokines and TNF-\u03b1: implications for atopic dermatitis","volume":"42","author":"Byrne","year":"2012","journal-title":"Clin Exp Allergy."},{"issue":"3","key":"10.1016\/j.intimp.2024.112663_b0760","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jaci.2005.11.037","article-title":"Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes","volume":"117","author":"Cardona","year":"2006","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112663_b0765","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2017.11.053","article-title":"Basophils from allergic patients are neither hyperresponsive to activation signals nor hyporesponsive to inhibition signals","volume":"142","author":"Cassard","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.intimp.2024.112663_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104581","article-title":"VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils","volume":"379","author":"Vivian Ma","year":"2022","journal-title":"Cell. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112663_b0775","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/j.jid.2019.02.037","article-title":"Silencing of PD-L2\/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity","volume":"139","author":"Furusawa","year":"2019","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.intimp.2024.112663_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108842","article-title":"The study of immune checkpoint inhibitors in chronic hepatitis B virus infection","volume":"109","author":"Li","year":"2022","journal-title":"Int Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112663_b0785","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.112663_b0790","first-page":"31","article-title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives","volume":"8","author":"Noisette","year":"2018","journal-title":"Psoriasis (auckl)."},{"issue":"10","key":"10.1016\/j.intimp.2024.112663_b0795","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"13","key":"10.1016\/j.intimp.2024.112663_b0800","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1177\/0961203316640911","article-title":"Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease","volume":"25","author":"Danion","year":"2016","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.intimp.2024.112663_b0805","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","article-title":"Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment","volume":"66","author":"Alten","year":"2014","journal-title":"Arthritis & Rheumatology (hoboken, NJ)."},{"issue":"2","key":"10.1016\/j.intimp.2024.112663_b0810","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis & Rheumatology (hoboken, NJ)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924011846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924011846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T02:21:48Z","timestamp":1732933308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924011846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":162,"alternative-id":["S1567576924011846"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112663","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112663"}}